

2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| LightX Capital Fund IFiled to raise in 2026, with no closing reported yet. | 2026 | Indefinite | $0 | 0 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
2 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Michael Liang | Slowing | Biotech & pharma, Digital health, Medical devices | 13 | 1 |
Categories of LightX Capital’s own portfolio companies, based on 19 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Baird Venture Partners | 2 | Amphora Medical, NEOCHORD |
| Versant Venture Capital | 2 | Alphaeon, RxSight |
| Andreessen Horowitz | 1 | |
| Arboretum Ventures |
| Christopher Cox | Quiet | Biotech & pharma, Fintech, Consumer apps & internet | 10 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of LightX Capital’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| 1 |
| JumpCode Genomics |
| ARCH Venture Partners | 1 | Areteia Therapeutics |
| Bain Capital Life Sciences | 1 | Areteia Therapeutics |
| BioStar Ventures | 1 | NEOCHORD |
| Canapi Ventures SBIC | 1 | Apiture Co-Investment |
| Founders Fund | 1 |
| Longitude Capital | 1 | Infinant Health |
| Oak HC/FT | 1 | Oncology Analytics |
| Sandbox Clinical Ventures | 1 | Oncology Analytics |
| SNAK Venture Partners | 1 | APERVITA |
| Treo Ventures | 1 | NEOCHORD |
| U.S Venture Partners | 1 | NEOCHORD |
A shared board seat: a company where filings name a LightX Capital partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.